- Pharmaceutical company AstraZeneca has admitted, in court documents filed as part of a class-action suit against it, that its COVID vaccine can produce a rare adverse effect. The Telegraph
- In response to the suit accusing its jab of causing dozens of deaths and injuries, AstraZeneca — in documents presented to the UK High Court — said the jab can "in very rare cases" cause Thrombosis with Thrombocytopenia Syndrome, which causes blood clots and low platelet counts. WION
- Fifty-one High Court claims have been filed by victims and bereaved relatives who are seeking up to £100M ($125M) in damages over what they say is a "defective" and "vastly overstated" vaccine. AstraZeneca disputes these charges. The Telegraph
- Health officials linked immunization to vaccine-induced thrombocytopenia and thrombosis (VITT) shortly after the jabs were released in March 2021, but AstraZeneca previously denied VITT as a TTS subtype. Daily Mail (LR: 5 CP: 5)
- Data from the Medicines and Healthcare products Regulatory Agency (MHRA) reported 81 UK deaths that were thought to have been caused by an adverse reaction to the vaccine, which caused clotting in persons with low blood platelets. The MHRA reported more than 20% of those died. The Telegraph
- In the first year of the pandemic, independent research found that AstraZeneca's vaccine prevented over 6M deaths. However, the UK is not currently using the AstraZeneca vaccine. The Telegraph
Narrative A:
- AstraZeneca has always acknowledged this could be a very rare side effect of the jab. However, there could be other contributing factors to patients developing Thrombocytopenia Syndrome. Aside from the few instances where recipients may have suffered this side effect, the vaccine has saved millions wherever it was distributed.
NEW YORK POST (LR: 5 CP: 5)
Narrative B:
- As the claimants in this case can attest, AstraZeneca downplayed the risk of this vaccine while exaggerating its effectiveness. Otherwise healthy people have faced the consequences of these side effects and the pharmaceutical firm must compensate the ones who survived their unnecessary medical crises.
SKY NEWS
Nerd narrative:
- There's a 90% chance that before Jan. 1, 2032, an intranasal SARS-CoV-2 vaccine candidate will be approved by the USA, UK, EU, or Canada, according to the Metaculus prediction community.
METACULUS (LR: 3 CP: 3)